BioSig Technologies (NASDAQ:BSGM) announced its quarterly earnings results on Monday. The company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.03), Fidelity Earnings reports.
Shares of NASDAQ BSGM traded down $0.12 during midday trading on Wednesday, reaching $6.46. The stock had a trading volume of 63 shares, compared to its average volume of 57,829. BioSig Technologies has a twelve month low of $3.50 and a twelve month high of $7.88.
In other news, CEO Kenneth L. Londoner purchased 18,700 shares of the company’s stock in a transaction dated Tuesday, January 22nd. The shares were purchased at an average price of $4.35 per share, for a total transaction of $81,345.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 26.70% of the stock is currently owned by insiders.
BioSig Technologies Company Profile
BioSig Technologies, Inc, a development stage medical device company, engages in developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. Its product is PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes, and displays electrocardiogram and electrograms required during electrophysiology studies and catheter ablation procedures.
Further Reading: How to Invest in an Index Fund
Receive News & Ratings for BioSig Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSig Technologies and related companies with MarketBeat.com's FREE daily email newsletter.